SOUTH SAN FRANCISCO, Calif., April 06, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the 15th Annual Needham Health Care Conference taking place April 12 to 13, 2016 at the Westin NY Grand Central Hotel, New York, NY. Achaogen’s management will present at 10:40 a.m. Eastern Time on Wednesday, April 13th, 2016.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived for 30 days following the conference for those unable to listen live.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
AKAO-G
Investor Contact:
Hans Vitzthum
212.915.2568
hans@lifesciadvisors.com
Media Contact:
Denise Powell
510.703.9491
denise@redhousecomms.com
